Episodic dyscontrol syndrome
Abstract
Episodic dyscontrol syndrome (EDS) or intermittent explosive disorder (IED) is a clearly identified category in the Diagnostic and Statistical Manual of Mental Disorders (DSM IV). It affects children and adults. Children are often considered to have epilepsy or a mental health problem. The episodes comprise of recurrent attacks of uncontrollable rage, usually after minimal provocation, and may last up to an hour. Following an episode, children are frequently exhausted, may sleep and will usually have no recall. These features often raise the possibility of epilepsy, and children may be referred for an electroencephalogram (EEG). An abnormal EEG may subsequently lead to a diagnosis of epilepsy and the prescription of an anticonvulsant. Five patients with EDS are described, all referred to a single neurology clinic with a possible diagnosis of epilepsy, one of whom was being treated with an anticonvulsant. Four had an EEG, which was normal in two patients and showed "abnormalities" in two, leading to an incorrect diagnosis of temporal lobe epilepsy in one patient. All five children responded to psychological (behavioural) intervention. Recognition of the clinical features of IED/EDS should preclude the need for EEG and other investigations in these patients and prompt referral to psychological services.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.